The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 28 March 2026•Updated 28 March 2026•

1 min read

Arrowhead Pharmaceuticals Reports Positive Two-Year Data for Plozasiran

Key Facts

1Arrowhead Pharmaceuticals announced long-term two-year efficacy and safety data for the investigational drug plozasiran.

2 months ago

Version History

Version 12 months ago

What changed: Updated the story to include the specific regulatory submission timeline (late 2026) and safety data confirming zero acute pancreatitis events.

Arrowhead Pharmaceuticals (ARWR) presented two-year efficacy and safety data for plozasiran during the American College of Cardiology's 75th Annual Scientific Session. Crucially, the study confirmed zero adjudicated acute pancreatitis events during the observation period, significantly bolstering the drug's safety profile. The updated data also highlighted specific efficacy in reducing atherogenic lipoproteins, addressing a key cardiovascular risk factor. Following these results, the company announced it is targeting year-end 2026 for its supplemental New Drug Application (sNDA) submission. Analysts believe the combination of sustained clinical performance and a concrete regulatory timeline reduces the risk profile for this lead asset. These findings strengthen the investment case for plozasiran as a durable therapeutic solution for hypertriglyceridemia.